Streetbeat News

Revenues

MOS

Recent analyst evaluations of Mosaic (NYSE:MOS) show diverse opinions, with a mix of bullish, somewhat bullish, and indifferent ratings. The average 12-month price target for MOS has been adjusted to $39.00, down from $45.00, indicating a 13.33% decrease. Analysts from Scotiabank, Goldman Sachs, Mizuho, and Wells Fargo have provided updates, with some lowering their price targets. Mosaic's financial indicators suggest challenges in revenue growth, profitability, and asset utilization, despite a strong market presence.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 3:00 pm

SPY

USA existing home sales in January increased to 4.00 million, surpassing the estimated 3.96 million and the previous month's 3.88 million.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 3:00 pm

HOV

Hovnanian Enterprises expects its Q2 revenues to be in the range of $675M-$775M, with an adjusted homebuilding gross margin forecasted to be between 21.5% and 23.0%.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 2:19 pm

HOV

Hovnanian Enterprises reported a 28.76% increase in Q1 EPS to $2.91 from $2.26 YoY and a 15.30% increase in sales to $594.20M from $515.37M YoY.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 2:16 pm

SMTI

Sanara MedTech announced preliminary Q4 2023 revenue of approximately $17.7 million, surpassing the estimated $16.50 million.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 2:16 pm

NVRO

Analyst ratings for Nevro (NYSE:NVRO) over the last quarter show a mix of sentiments, with 1 somewhat bullish and 3 indifferent ratings. The average 12-month price target is $22.25, down from $22.50, indicating a slight negative sentiment. Analyst actions include both raises and lowers in ratings and price targets, reflecting ongoing adjustments to market conditions and company performance. Nevro's financial performance shows a revenue growth of 3.38% for the last quarter, a net margin of -22.61%, and challenges in ROE and ROA compared to industry averages.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 2:00 pm

UTHR

United Therapeutics (NASDAQ:UTHR) has been analyzed by 4 analysts, showing a mix of bullish to indifferent ratings. The average 12-month price target is $288.25, marking a 35.33% increase from the previous target of $213.00. Analysts from Wedbush, HC Wainwright & Co., Goldman Sachs, and Leerink Partners have provided ratings and price targets, reflecting varied expectations for UTHR's performance. The company, focusing on pulmonary arterial hypertension treatments, shows a revenue growth of 18.1% but falls below industry averages in market capitalization, net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 2:00 pm

TNC

Tennant Company projects its 2024 net sales to be between $1.27 billion and $1.295 billion, slightly below the estimated $1.292 billion. The company also forecasts its adjusted EPS to range from $6.05 to $6.65, with an estimate at $6.26.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 2:00 pm

UFPI

Recent analyst evaluations of UFP Industries (NASDAQ:UFPI) show diverse opinions, with the latest 12-month price targets ranging from $102.00 to $137.00, averaging $119.75. This marks an increase from the previous average of $115.67. Analysts' actions include maintaining and raising ratings, reflecting their adaptation to market conditions and UFP Industries' performance. Despite facing challenges in revenue growth and profitability, UFP Industries maintains a strong ROA and a conservative debt management approach.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 2:00 pm

TNC

Tennant Company aims for a 2%-4% organic net sales growth in 2024, with an equal contribution from price and volume growth.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:58 pm